Latest news for Rogue One Inc (OTC:ROAG) Stock

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

HGBL

NBRV

PFMT

ROAG

TCON

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

5 Penny Stocks Insiders Are Buying

Rogue One Inc

WIIM

VRNS

Varonis Systems shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 guidance.

UBS analyst Steven Fisher downgrades Centuri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) from Buy to Neutral and lowers the price target from $30 to $17.

Downgrades

Price Target

Analyst Ratings

CTRI

UBS Downgrades Centuri Holdings to Neutral, Lowers Price Target to $17

Symbiotic shares are trading lower after the company reported worse-than-expected Q3 earnings results and issued Q4 revenue guidance below estimates.

Earnings

Earnings Beats

Earnings Misses

Intl Game Tech Q2 2024 Adj. EPS $0.36 Beats $0.32 Estimate, Sales $1.049B Miss $1.059B Estimate

UBS analyst Jason Napier downgrades Lloyds Banking Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYG#NYSE">LYG</a>) from Buy to Neutral.

UBS Downgrades Lloyds Banking Group to Neutral

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and raises the price target from $40 to $45.

CORT

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $45

Needham analyst Mike Matson reiterates NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Buy and maintains $19 price target.

Reiteration

Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target

Merck shares re trading higher following a Q2 earnings beat but mixed guidance.

Seaport Global analyst Sunil Sibal downgrades Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) from Buy to Neutral.

Seaport Global Downgrades Williams Companies to Neutral

AMKR

Amkor Technology shares are trading lower after the company issued roughly inline guidance.

For the full year of 2024, Civeo is maintaining its previously provided revenue and Adjusted EBITDA&nbsp;guidance&nbsp;ranges of&nbsp;$625 million&nbsp;to&nbsp;$700 million&nbsp;and&nbsp;$80 million&nbsp;to&nbsp;$90 million, respectively. The Company is also maintaining its full year 2024 capital expenditure&nbsp;guidance&nbsp;of&nbsp;$30 million&nbsp;to&nbsp;$35 million.

Guidance

CVEO

Civeo Is Maintaining Previously Provided FY24 Revenue Guidance Range Of $625M-$700M Vs. $665.18M Estimate

Biotech

Large Cap

Health Care

General

Merck Expects 2024 Adjusted EPS Of $7.94-$8.04 Compared To Prior Guidance Of  $8.53-$8.65 And Consensus Of $8.16, Includes One-time Charges Totaling $0.77 Per Share For The Harpoon And Eyebio Acquisitions

Citigroup analyst Joanne Wuensch downgrades Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) from Neutral to Sell and lowers the price target from $30 to $23.

IART

Citigroup Downgrades Integra Lifesciences to Sell, Lowers Price Target to $23

SITE Centers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.24 by 12.5 percent. This is a 6.9 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $114.129 million which beat the analyst consensus estimate of $113.504 million by 0.55 percent. This is a 16.32 percent decrease over sales of $136.383 million the same period last year.

SITC

SITE Centers Q2 2024 FFO $0.27 Beats $0.24 Estimate, Sales $114.129M Beat $113.504M Estimate

LSCC

Lattice Semiconductor shares are trading lower after the company reported worse-than-expected Q2 financial results and issued weak Q3 revenue guidance.

Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>) reported quarterly earnings of $3.94 per share which beat the analyst consensus estimate of $3.78 by 4.23 percent. The company reported quarterly sales of $608.689 million which missed the analyst consensus estimate of $624.182 million by 2.48 percent. This is a 1.19 percent increase over sales of $601.521 million the same period last year.

Eagle Materials Q1 2025 GAAP EPS $3.94 Beats $3.78 Estimate, Sales $608.689M Miss $624.182M Estimate

Needham analyst Ryan Koontz reiterates Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) with a Buy and maintains $18 price target.

HLIT

Needham Reiterates Buy on Harmonic, Maintains $18 Price Target

Full-Year 2024 Financial Outlook
The following table summarizes the company&#39;s full-year financial outlook.
<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="2" rowspan="1">
Full Year 2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
Updated
</td>
<td colspan="1" rowspan="1">
Prior
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Sales&#x2A;
</td>
<td colspan="1" rowspan="1">
$63.4 to $64.4 billion
</td>
<td colspan="1" rowspan="1">
$63.1 to $64.3 billion
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP Gross margin2
</td>
<td colspan="1" rowspan="1">
Approximately 81%
</td>
<td colspan="1" rowspan="1">
Approximately 81%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAPOperating expenses2&#x2A;&#x2A;
</td>
<td colspan="1" rowspan="1">
$26.8 to $27.6 billion
</td>
<td colspan="1" rowspan="1">
$25.2 to $26.1 billion
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAPOther (income) expense, net2
</td>
<td colspan="1" rowspan="1">
Approximately $350 million expense
</td>
<td colspan="1" rowspan="1">
Approximately $250 million expense
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAPEffective tax rate2
</td>
<td colspan="1" rowspan="1">
15.5% to 16.5%
</td>
<td colspan="1" rowspan="1">
14.5% to 15.5%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAPEPS2&#x2A;&#x2A;&#x2A;
</td>
<td colspan="1" rowspan="1">
$7.94 to $8.04
</td>
<td colspan="1" rowspan="1">
$8.53 to $8.65
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Share count (assuming dilution)
</td>
<td colspan="1" rowspan="1">
Approximately 2.54 billion
</td>
<td colspan="1" rowspan="1">
Approximately 2.55 billion
</td>
</tr>
</tbody>
</table>

Merck Expects 2024 Sales Of $63.4B-$64.4B Compared To Prior Guidance Of $63.1B-$64.3B And Consensus Of $64.341B

TLRY

Tilray Brands shares are trading higher after the company reported better-than-expected Q4 financial results.

B of A Securities analyst Blake Friedman downgrades Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) from Neutral to Underperform and lowers the price target from $83 to $47.

B of A Securities Downgrades Lattice Semiconductor to Underperform, Lowers Price Target to $47

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.

<h2>TRACON Pharmaceuticals </h2>

<ul>
	<li>The Trade: TRACON Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) 10% owner Opaleye Management Inc <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 107450.304 shares </a> at an average price of $2.87. To acquire these shares, it cost $308,052.20.</li>
	<li>What&rsquo;s Happening: The company recently announced results from the Independent Data Monitoring Committee review of interim safety and efficacy data from the ongoing ENVASARC pivotal trial.</li>
	<li>What TRACON Pharmaceuticals Does: TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States.</li>
</ul>

<h2>Rogue One </h2>

<ul>
	<li>The Trade: Rogue One Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ROAG#OTC">ROAG</a>) COO Janon Costley <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 4039380 shares </a> at an average price of $0.05. The insider spent $201,969.00 to buy those shares.</li>
	<li>What&rsquo;s Happening: The company&rsquo;s stock gained more than 16% over the previous month.</li>
	<li>What Rogue One Does: Rogue One Inc formerly Fresh Promise Foods Inc through its subsidiaries is a consumer products and marketing company focused on the health and wellness food and beverage sectors.</li>
</ul>

<h2>Heritage Global </h2>

<ul>
	<li>The Trade: Heritage Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGBL#NASDAQ">HGBL</a>) Director Barbara A Sinsley <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 3512 shares </a> at an average price of $1.50. To acquire these shares, it cost $5,268.00.</li>
	<li>What&rsquo;s Happening: The company, last month, posted downbeat quarterly results.</li>
	<li>What Heritage Global Does: Heritage Global Inc is a diversified financial services company. The firm provides acquisition, disposition, valuation, and lending services for surplus and distressed assets.</li>
</ul>

<h2>Performant Financial </h2>

<ul>
	<li>The Trade: Performant Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFMT#NASDAQ">PFMT</a>) 10% owner Phil Frohlich <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 544542 shares </a> at an average price of $2.28. The insider spent $1,241,679.99 to buy those shares.</li>
	<li>What&rsquo;s Happening: Performant Financial recently announced $35 million debt refinancing.</li>
	<li>What Performant Financial Does: Performant Financial Corp provides technology-enabled recovery and related analytics services in the United States. The company provides its services on an outsourced basis where it handles many or all aspects of its clients&#39; recovery processes.</li>
</ul>

<h2>Nabriva Therapeutics </h2>

<ul>
	<li>The Trade: Nabriva Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBRV#NASDAQ">NBRV</a>) CEO Theodore Schroeder <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 100000 shares </a> shares at an average price of $0.57. The insider spent $57,320.00 to buy those shares.</li>
	<li>What&rsquo;s Happening: The company&rsquo;s shares have dropped over 78% since the start of the year.</li>
	<li>What Nabriva Therapeutics Does: Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics.</li>
</ul>

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Rogue One Inc

News

Latest news for Rogue One Inc (OTC:ROAG) Stock

Thursday, December 30, 2021